key: cord-0934736-5qe33dr3
authors: Livingstone, Robert; Lin, Hlaing; Brendish, Nathan J; Poole, Stephen; Tanner, Alex R; Borca, Florina; Smith, Trevor; Stammers, Matthew; Clark, Tristan W
title: Routine molecular point-of-care testing for SARS-CoV-2 reduces hospital-acquired COVID-19
date: 2022-01-31
journal: J Infect
DOI: 10.1016/j.jinf.2022.01.034
sha: a5406fee6a649949336eac195a8a344322e637a6
doc_id: 934736
cord_uid: 5qe33dr3

OBJECTIVES: Risk of hospital-acquired COVID-19 (HA-COVID-19) infection is increased by cohorting infected and non-infected patients together in assessment areas, whist awaiting laboratory PCR results. Molecular point-of-care tests (mPOCT) reduce time to results and improve patient flow but the impact on HA-COVID-19 is unknown. METHODS: In this pre and post implementation study patients were evaluated across two time periods: March 1(st) to August 13(th) 2020, prior to the introduction of mPOCT in medical admissions areas, and 14(th) August 2020 to 1(st) April 2021, after mPOCT introduction. The primary outcome was proportion of HA-COVID-19 infection among all COVID-19 positive patients. Secondary outcome measures included time to SARS-CoV-2 results, length of time spent in the medical assessment area and comparison of local, regional and national proportions of HA-COVID-19. RESULTS: 1988 patients were admitted through the acute medicine admission cohorting area and tested for SARS-CoV-2 prior to introducing mPOCT and 4640 afterwards. Median (IQR) time to SARS-CoV-2 result was 6.5 (2.1-17.9) hours prior to introducing mPOCT and 1.0 (0.8-1.3) hours afterwards (p<0.0001). Median (IQR) duration in the assessment cohort area was 12.0 (4.8-20.6) hours prior to introduction of POCT and 3.2 (2.0-5.6) hours afterwards (p<0.0001). The proportion of hospital-acquired COVID-19 cases was 108 (16.5%) of 654 prior to introducing mPOCT compared with 168 (9.4%) of 1782 afterwards, (HR 0.55, 95%CI 0.43-0.70; p<0.0001). In the period following the introduction of mPOCT up to 1(st) April 2021 the median proportion of HA-COVID-19 was 13.6% (95%CI 8.2% - 18.9%) locally, compared with 43.8% (95%CI 37.8%-49.9%) for all acute NHS trusts regionally and 30.9% (95%CI 28.4%-33.5%) for all NHS trusts nationally, CONCLUSIONS: Routine mPOCT for SARS-CoV-2 was associated with reduced time to results, time spent in admission cohort areas, and hospital-acquired COVID-19, compared to laboratory PCR.

Timely recognition and management of COVID-19, caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is critical in preventing onward transmission to other patients in hospital [1] . NHS data suggests that by May 2021 over 32,000 hospital-acquired COVID-19 cases had occurred with nearly 9000 associated deaths [2] . A recent nationwide study has estimated that during the first wave of the pandemic 11 .3% of patient with COVID-19 in UK hospitals had acquired their infection in hospital [3] .

In addition, genome sequencing-based studies from the UK suggest that the vast majority of hospital-acquired COVID-19 (HA-COVID-19) originates from patient-to-patient transmission [4] .

Although multiple factors are implicated in hospital transmission of SARS-CoV-2, delays in SARS-CoV-2 test results have been recognised as being among the leading causes [1, 5] . The risk of patient-to-patient transmission is increased when single room capacity is exceeded by the number of suspected cases with an unconfirmed COVID-19 status as this leads to the practice of cohorting of acute hospital admissions in assessment wards whilst awaiting SARS-CoV-2 results, inadvertently leading to co-location of infected and non-infected patients in shared bay areas. Reducing the amount of time that patients spend in assessment cohort areas is therefore key to reducing both patient-to-patient transmission. Rapid downstream flow of SARS-CoV-2 positive patients to designated COVID-19 wards allows optimal use of facilities providing patient isolation, adequate ventilation, and clinical care from designated staff with appropriate personal protective equipment [1] .

Centralised laboratory SARS-CoV-2 polymerase chain reaction (PCR) testing is associated with long delays in returning results, representing the rate-limiting step in effective patient flow through the hospital [6] . Molecular point-of-care testing (mPOCT) has been shown to significantly reduce the time from admission to test results for SARS-CoV-2 and to reduce the length of time spent in assessment cohort areas, however its effect on HA-COVID-19 is unknown [6] .

We performed a single centre, pre and post implementation study in a tertiary hospital in the UK. We analysed the records of all medical admissions tested for SARS-CoV-2 with laboratory PCR or mPOCT, and all positive cases across specialities, between 1 st March 2020 and 1 st April 2021 at University Hospital Southampton Foundation Trust (UHSFT), a large acute teaching hospital in the South of England serving a population of 1.9 million [7] .

Following local R&D governance review formal application for ethical approval was deemed unnecessary, as only routinely collected, pseudo-anonymised data was used, this study was prospectively approved by senior trust governance. Ref No: SEV/0320.

Routine molecular point-of-care testing for SARS-CoV-2 and other respiratory viruses was introduced on the 13 th August 2020 for patients admitted under the department of medicine via the acute medical admission pathway. Following device validation and a period of staff training all patients admitted to the Acute Medical Unit (AMU) had a nose and throat swab taken at arrival and tested using the BioFire (Salt Lake City, USA) FilmArray Respiratory 

Patients were analysed over two time periods: from March 1st, 2020 to August 13th, 2020, prior to introducing routine use of mPOCT in the AMU, when medical patients were tested for SARS-CoV-2 using laboratory testing within the on-site PHE microbiology laboratory, and August 14th 2020 to April 1st 2021, after the introduction of routine mPOCT in the AMU. For both periods, patients admitted outside of the acute medical admissions pathway were tested with laboratory PCR.

The 

For the primary outcome, analysis of proportion of HA-COVID-19 infection was undertaken in all hospitalised COVID-19 patients at UHSFT. This included all patients over the study period admitted under any hospital speciality, testing positive for SARS-CoV-2. Patients who were admitted directly to the intensive care unit or not admitted to a downstream hospital ward were excluded.

For the secondary outcomes, analyses of time to results and time spent in the AMU assessment area were undertaken in all patients admitted under the department of medicine via the acute medical admission pathway and tested for SARS-CoV-2 with laboratory PCR or mPOCT.

Baseline characteristic data was collected for all patients including age, gender, ethnicity, comorbidities and body mass index (BMI). Binary variables were derived for comorbidities from the casemix database using the appropriate codes for: previous myocardial infarction, congestive cardiac failure, peripheral vascular disease, previous stroke or TIA, dementia, COPD, connective tissue disease, peptic ulcer disease, liver disease, diabetes, hemiplegia, chronic kidney disease, cancer (solid/lymphoma/metastatic) and HIV/AIDS. These were used to calculate the Charlson Comorbidity Index (CCI) for each patient.

Data was retrieved to flag use of mPOCT at admission and those patients on a non-medical admission pathway as defined by specialty destination ward code to exclude this as a potential confounder.

Data were extracted from structured and/or unstructured components of the electronic health record (EHR) at our institution. All data was handled securely on-site using python 3.7 and associated packages. Further details regarding data processing including pseudonymisation are presented in the supplementary materials -Supplement A.

Analysis was done using Prism version 9.2 (GraphPad Software Inc; La Jolla, California), and Python version 3.7 + packages. All continuous parameters were summarised using either mean or median and interquartile range (IQR) as appropriate. Proportions and confidence intervals were used for categorical data. The Mann-Whitney U test was used to compare medians and mean differences and corresponding CIs were calculated with the Hodges-Lehmann estimate. Groups were compared using chi-square tests or Fishers exact test for equality of proportions, as appropriate based on group size.

We evaluated time from hospital admission to hospital-acquired infection amongst the COVID-19 positive patients accounting for competing risks and right-censored data (i.e. patients still in hospital at the time of censoring) using the Nelson-Aelen and Kaplan-Meier estimators, respectively. We used adjusted and unadjusted cox proportional hazards regression to assess predictors of risk for hospital-acquired COVID-19 infection and their impact compared to our primary covariate -mPOCT. Variables with a p value below 0.05 in adjusted regression were considered significant. Variables such as BMI with a greater than 20% rate of missingness were excluded from regression analysis. The proportional hazards assumptions were evaluated using Schoenfeld's residuals [9] . The Ljung-Box and Box-Pierce tests were used to prove that the residuals were not autocorrelated.

The funders of the study had no role in the study conception, design, conduct, data analysis, or manuscript preparation. The corresponding author had full access to all data and the final responsibility to submit for publication.

We identified 6944 patients admitted and tested for SARS-CoV-2 through the acute medical Table 2 . In the period following the introduction of mPOCT up to 1 st April 2021 the median proportion of HA-COVID-19, defined as PCR positivity >7 days after admission to hospital, was 13.6% (95% CI 8.2% -18.9%) at UHSFT compared with 43.8% (95% CI 37.8%-49.9%) for all acute NHS trusts in the South of England and 30.9% (95% CI 28.4%-33.5%) for all NHS trusts nationally, shown in Figure 7 .

To our knowledge, this real-world study is the first to assess the impact of routine use of mPOCT in an admission pathway, upon HA-COVID-19 infection rates. Consistent with the results of our previous trials, we have demonstrated that routine use of mPOCT in acute hospital admissions significantly reduced the time to SARS-CoV-2 results and the time that patients spent in assessment cohort areas [6] . In addition, we have also demonstrated in this study that that the introduction of mPOCT in our institution was associated with a large reduction in the rate of HA-COVID-19. Molecular point-of-care testing is likely to reduce HA-COVID-19 by providing a rapid accurate result, allowing patients with SARS-CoV-2 infection to be identified early and transferred to definitive care areas before they are able to transmit infection to other patients in the assessment areas. According to nationally available data [10] 280,737 patients were admitted to hospital or diagnosed with COVID-19 whilst in hospital in England during our study period. Based on these data 86,832 of these patients are likely to have contracted COVID-19 in hospital. Extrapolating from our data around 52,100 of these infections could have been prevented by nationally deploying mPOCT for acute admissions, potentially resulting in 13,025 fewer COVID-19 related deaths. Although the availability of mPOCT test platforms for SARS-CoV-2 was severely limited during the early part of the pandemic, there are now several widely available test platforms with high levels of accuracy demonstrated though national validation [11] that can be deployed in hospitals at the point-of-care or in near-patient settings.

The strengths of the study include its real-world nature. We have performed a pre and post implementation study in a typical acute NHS setting with a large number of patients over a prolonged period of time, suggesting that our results are generalisable to similar UK and international centres. Our study also has a number of potential weaknesses. It was observational, not interventional, and outside the setting of a randomised control interventional trial we are unable to definitively attribute the observed reduction in hospitalacquired COVID-19 infection rates to the introduction of routine mPOCT. There were potential confounding variables within our study as it took place during a period of time with a rapidly changing landscape as the United Kingdom responded to the COVID-19 pandemic.

Following the first waves of the pandemic there were a number of changes introduced during the study period in addition to mPOCT that could have influenced HA-COVID-19 rates including staff screening, changes to PPE and infection control practices and staff and community vaccination programmes. We have attempted to control for these by comparing HA-COVID-19 with mPOCT and laboratory testing after the introduction of mPOCT and also by including regional and including national data. As most of these interventions were introduced nationally and at the same time, the lack of a fall in HA-COVID-19 either regionally or nationally over the study period suggests that the changes seen at UHSFT were the result of mPOCT rather than other interventions.

At the end of December 2020, the SARS-CoV-2 lineage B.1.1.7 (VOC 202012/01, 'alpha variant') became the dominant SARS-CoV-2 lineage in the UK [12] . This may also be a confounding factor as altered strain dynamics may impact upon likelihood of nosocomial transmission. Notably, this variant has been associated with increased transmissibility [13] when compared with prior lineages, and therefore is unlikely to be associated with a reduction in hospital-acquired cases. We did not routinely analyse sequencing data from cases within this study, but the local prevalence of the alpha variant was already >50% by 

TWC has received speaker fees, honoraria, consultancy fees, travel reimbursement, and equipment and consumables free of charge for the purposes of research outside of this submitted study, from BioFire diagnostics and BioMerieux. He has received speaker fees and discounted equipment and consumables from QIAGEN. He has received consultancy fees from Shionogi, Synairgen research, Randox laboratories and Cidara therapeutics. He has been a member of advisory boards for Roche, Janssen and Cepheid. He is a member of two independent data monitoring committees for trials sponsored by Roche. He has acted as the UK chief investigator for a trial sponsored by Janssen

The data analysed and presented in this study are available from the corresponding author on reasonable request, providing this meets local ethical and research governance criteria. 14. World Health Organization. Prevention of hospital-acquired infections : a practical guide [Internet] 

COVID-19 transmission in hospitals: management of the risk -a prospective safety investigation

Up to 8,700 patients died after catching Covid in English hospitals

Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. The Lancet

Superspreaders drive the largest outbreaks of hospital onset COVID-19 infections

Could we do better on hospital-acquired covid-19 in a future wave?

Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. The Lancet Respiratory Medicine

Chief Inspector praises 'impatience to improve' at University Hospitals Southampton NHS Foundation Trust | Care Quality Commission

Healthcare associated COVID-19 infections -further actions

Partial Residuals for The Proportional Hazards Regression Model

National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests

Infection Survey: estimates of COVID-19 cases to 23 December for England, regions of England and by cases compatible with the new variant -Office for National Statistics

All data are presented as n (%), median [interquartile range] or mean (SD). CI, confidence interval. BMI, body mass index. BAME, black and minority ethic. COPD, chronic obstructive airways disease. CKD, chronic kidney disease. IHD, ischaemic heart disease

Chi squared or Fisher's Exact Test. b Assessed in 494 and 1255 patients in the pre and post implementation groups respectively. c Assessed in 581 and 1551 patients in the pre and post implementation groups respectively

We would like to acknowledge all the clinical and laboratory staff at UHSFT and the patients.

This study was funded by University Hospital Southampton NHS Foundation Trust.